Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

Parkinson's disease-associated alpha-synuclein is a calmodulin substrate.

Martinez J, Moeller I, Erdjument-Bromage H, Tempst P, Lauring B.

J Biol Chem. 2003 May 9;278(19):17379-87. Epub 2003 Feb 27.

2.
3.

Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.

Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr.

Biochemistry. 2001 Jul 3;40(26):7812-9.

PMID:
11425308
4.

Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.

Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M.

J Biol Chem. 1999 Apr 2;274(14):9843-6. Erratum in: J Biol Chem 1999 May 7;274(19):13728.

5.

alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.

Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL.

J Biol Chem. 1999 Jul 9;274(28):19509-12.

6.

Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs.

Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu GM, Louis JC, Martin F, Narhi LO, Citron M.

J Biol Chem. 2000 Nov 3;275(44):34574-9.

7.

Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies.

Sharma N, McLean PJ, Kawamata H, Irizarry MC, Hyman BT.

Acta Neuropathol. 2001 Oct;102(4):329-34.

PMID:
11603807
8.

Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease.

Hegde ML, Jagannatha Rao KS.

Arch Biochem Biophys. 2003 Oct 15;418(2):169-78. Review.

PMID:
14522588
9.

The cellular pathology of Parkinson's disease.

Takahashi H, Wakabayashi K.

Neuropathology. 2001 Dec;21(4):315-22. Review.

PMID:
11837539
10.
11.

Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein.

Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, Nussbaum RL.

J Biol Chem. 2002 Feb 22;277(8):6344-52. Epub 2001 Dec 14.

12.

Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.

Liu IH, Uversky VN, Munishkina LA, Fink AL, Halfter W, Cole GJ.

Glycobiology. 2005 Dec;15(12):1320-31. Epub 2005 Jul 21.

PMID:
16037493
13.

Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations.

Kawamata H, McLean PJ, Sharma N, Hyman BT.

J Neurochem. 2001 May;77(3):929-34.

14.

Caught in the act: alpha-synuclein is the culprit in Parkinson's disease.

Eriksen JL, Dawson TM, Dickson DW, Petrucelli L.

Neuron. 2003 Oct 30;40(3):453-6. Review.

15.

alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro.

Turnbull S, Tabner BJ, El-Agnaf OM, Moore S, Davies Y, Allsop D.

Free Radic Biol Med. 2001 May 15;30(10):1163-70.

PMID:
11369507
16.

Alpha-synuclein and the pathogenesis of Parkinson's disease.

Martin FL, Williamson SJ, Paleologou KE, Allsop D, El-Agnaf OM.

Protein Pept Lett. 2004 Jun;11(3):229-37. Review.

PMID:
15182224
17.

Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.

Koo HJ, Choi MY, Im H.

Biochem Biophys Res Commun. 2009 Aug 14;386(1):165-9. doi: 10.1016/j.bbrc.2009.06.002. Epub 2009 Jun 6.

PMID:
19501571
18.

Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease.

Uversky VN, Li J, Bower K, Fink AL.

Neurotoxicology. 2002 Oct;23(4-5):527-36.

PMID:
12428725
19.

alpha-Synuclein exhibits competitive interaction between calmodulin and synthetic membranes.

Lee D, Lee SY, Lee EN, Chang CS, Paik SR.

J Neurochem. 2002 Sep;82(5):1007-17.

20.

Supplemental Content

Support Center